The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

BB Biotech reported a net loss of CHF 241 mn for Q1 2025. The share price closed the quarter at a 14.1% discount to NAV, broadly in line with year-end 2024. The share price performance for the quarter ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...

Global Data has revealed that the Top 20 Global Biopharmaceutical Companies have witnessed a 6 % growth in market ...

"There were no layoffs to scientists or food inspectors," FDA Commissioner Dr. Marty Makary told CNN on Wednesday. Makary previously said in an April 17 interview with Megyn Kelly that there "were ...

Kennedy Jr.'s goals to swap them out with natural alternatives in the U.S. food supply. The FDA's move stops short of the outright ban that had been floated for in Kennedy's "Make America Healthy ...

Investors eye Vertex’s Q1 for Alyftrek and Journavx momentum amid Trikafta’s international headwinds. Vertex stock shows a bullish technical bias despite recent pullback and mixed short-term ...

Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the rejection of the biotech's stomach disorder drug last year. The FDA has ...

The FDA issued a public alert on Tuesday concerning generic versions of a widely-used hair loss drug that is frequently distributed by popular telehealth brands like Hims and Keeps. The agency ...

Many conservatives want the FDA to impose tighter restrictions on mifepristone and misoprostol, which can be delivered by mail. The medication accounted for 63 percent of U.S. abortions in 2023.